FDA approved new oral therapy: Delay functional decline of ALS by 33%
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
FDA approved new oral therapy: Delay functional decline of ALS by 33%
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA approved new oral therapy: Delay functional decline of ALS by 33%.
On May 14, Mitsubishi Tanabe Pharma America (MTPA) announced that the U.S. FDA has approved the marketing of oral Edaravone (Brand name Radicava ORS) for the treatment of amyotrophic lateral sclerosis (ALS). This is a rapidly progressive neurodegenerative disease that currently has no cure.
In a pivotal clinical trial, Radicava ORS demonstrated the same efficacy in slowing physical decline compared to an FDA-approved intravenous formulation.
According to the press release, the oral formulation provides ALS patients with a flexible way of administering medication, either orally or through a feeding tube, and does not require dose adjustments.
ALS is a neurodegenerative disease in which muscle function is lost due to the death of motor neurons in the brain and spine.
Patients have an average life expectancy of 2 to 5 years after diagnosis, and treatment options are currently lacking.
The intravenous dosage form of Edaravone was approved by the US FDA in 2017. Its mechanism of action is still not fully elucidated and is thought to delay disease progression by reducing oxidative stress. Radicava ORS is an oral formulation made for ALS patients.
It is a 5 mL liquid formulation that can be taken orally using a syringe or infused into a feeding tube, and does not require refrigeration or be dissolved prior to use. With proper instruction, medical staff can administer the drug in just a few minutes.
The FDA approval is supported by multiple studies, including a pivotal Phase 3 clinical study evaluating 137 ALS patients. Trial results showed that after 24 weeks of treatment, Radicava ORS slowed the decline of physical function in patients by 33% compared with placebo.
▲ Phase 3 clinical trial results of Radicava ORS (Image source: Reference [2])
References:
[1] Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (Edaravone) for the Treatment of ALS. Retrieved May 13, 2022, from https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma- america-announces-fda-approval-of-radicava-ors-Edaravone-for-the-treatment-of-als-301546937.html
[2] Radicava ORS. Retrieved May 13, 2022, from https://www.multivu.com/players/English/9019751-mitsubishi-tanabe-pharma-america-fda-approval-radicava-ors/docs/ProductFactSheetPDF_1652425733568-13550661 .pdf
FDA approved new oral therapy: Delay functional decline of ALS by 33%
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
